Product Details

Uniprot No.

Q04695

Target Names

KRT17

Alternative Names

Keratin, type I cytoskeletal 17 (39.1) (Cytokeratin-17) (CK-17) (Keratin-17) (K17), KRT17

Species Reactivity

Human

Immunogen

A synthesized peptide from human KRT17 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

20E3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IF, FC

Recommended Dilution

Application	Recommended Dilution
IF	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Keratin 17 is a type I intermediate filament protein that plays a distinctive role in epithelial biology, particularly in hair follicles, nail beds, and other specialized epithelial structures. Beyond its structural functions, KRT17 has emerged as a significant marker in cancer research, where its aberrant expression patterns in various carcinomas—including basal cell carcinoma, cervical cancer, and certain breast cancer subtypes—make it a valuable target for both diagnostic and mechanistic studies. The protein also participates in wound healing responses and inflammatory skin conditions, positioning it at the intersection of developmental biology and disease pathology.

This recombinant monoclonal antibody, clone 20E3, offers the reproducibility that demanding research applications require. Generated against a synthetic peptide derived from human KRT17, the antibody is produced using recombinant technology, ensuring sequence-defined consistency across production lots. This eliminates the batch-to-batch variability that can compromise longitudinal studies or multi-site collaborations, allowing you to build on previous results with confidence.

Validation studies demonstrate reliable performance in both immunofluorescence and flow cytometry applications using human samples. In HeLa cells, immunofluorescence staining at dilutions between 1:50 and 1:200 reveals clear cytoplasmic localization patterns consistent with intermediate filament distribution. Flow cytometry analysis of the same cell line shows distinct positive population shifts compared to isotype controls, confirming specific target recognition in single-cell applications.

Whether you are investigating epithelial differentiation programs, characterizing tumor phenotypes, or exploring keratin dynamics in skin biology, this antibody provides a dependable tool for visualizing and quantifying KRT17 expression at the cellular level.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair. Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state. Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway. Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial 'stem cells'. Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors. May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation.

Gene References into Functions

A report of a recurrent mutation in the KRT17 gene found in a family with severe SM, which provides further evidence that some factors such as modifiers, androgenic stimulation and/or environment influence the phenotypes, and other genetic or proteomic conditions might also influence the final manifestations of the disease. PMID: 29218738
High CK17 expression is associated with lymph node metastasis in oral squamous cell carcinoma. PMID: 30066921
High expression of KRT17 is frequent in Lung adenocarcinoma tissues. PMID: 29991674
Narrow-band ultraviolet B irradiation could downregulate K17 expression by inhibiting the ERK1/2 and STAT3 signaling pathways. PMID: 29349514
Our results highlight KRT17 as a possible biomarker in gastric cancer promoting tumor growth, motility, and invasion, and suggest that KRT17 can be a valuable molecular target for development of anti-gastric cancer-specific therapies PMID: 28299464
The findings suggest that CK17, although not specific for differentiated vulvar intraepithelial neoplasia (dVIN), when combined with histologic findings, Ki-67, and p53 immunohistochemistry, can be a marker of vulvar dysplasia and serve as an adjunct in the diagnosis of dVIN. PMID: 27513074
Krt17 was demonstrated to contribute to areca nut-induced oral malignancy PMID: 27432155
TGFbeta/SMAD/miR-486-3p signaling axis in keratinocytes regulated K17 expression and cell proliferation. We conclude that the loss of miR-486-3p in psoriatic epidermis leads to K17 protein overexpression and contributes to the pathogenesis of psoriasis. PMID: 28642156
KRT17 promotes tumor cell growth, at least partially, through its anti-apoptotic effect as a result of the KRT17 overexpression by GLIs in oral squamous cell carcinoma (OSCC).. PMID: 28342001
TGF-beta1-induced CK17 enhances cancer stem cell-like properties rather than epithelial-mesenchymal transition in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway. PMID: 28703907
K17 is highly expressed in most cases of both invasive adenocarcinoma and in AIS and is a powerful, negative prognostic marker for patient survival. PMID: 28821199
the data suggest that the loss of Krt17 may foster an overall protective environment for lesion-prone cervical tissue. PMID: 27065324
High KR17 expression is associated with oral cancer. PMID: 27512993
K17 is expressed in a subset of triple-negative breast cancers, and is a marker of poor prognosis in patients with advanced stage and ER(-)/HER2(-) breast cancer. PMID: 27816721
MiR-138 may regulate K17 protein expression to affect cell proliferation and apoptosis by targeting hTERT gene in keratinocytes from psoriatic vulgaris patients. PMID: 27936398
The pattern of CK17 expression is a highly sensitive marker for distinguishing cutaneous lymphadenoma from basal cell carcinoma in small samples. PMID: 26968559
Cytokeratin 17 immunoexpression might have a role in evaluating surgical borders in some cases of actinic keratosis and Bowen disease. PMID: 26740287
Steatocystoma multiplex is associated with the R94C mutation in the KRTl7 gene, and is reported in a Chinese pedigree. PMID: 26165312
These findings suggest that CK17 is involved in the development and metastasis of papillary thyroid carcinoma PMID: 26191283
Case Report: polycystic kidney disease with steatocystoma multiplex. PKD1 mutations disrupt keratin 17 polymerization. PMID: 25111597
our findings establish that K17 functions specially among keratins as an oncoprotein by controlling the ability of p27(KIP1) to influence cervical cancer pathogenesis. PMID: 26109559
Data indicate that autoimmune regulator Aire mRNA transcripts are regulated in a keratin 17 (K17) dependent manner in skin tumor keratinocytes. PMID: 26168014
We conclude that K17 expression promotes oral squamous cell carcinoma cell growth and cell size but does not affect cell migration PMID: 25736868
Report overexpression of keratin 17 in premalignant and malignant squamous lesions of the cervix. PMID: 24051697
novel heterozygous mutation, p.L91P (c.272T>C) in the helix initiation motif, associated with pachyonychia congenita type 2 PMID: 23855588
Peripheral or diffuse staining for CK17 is a useful marker of invasion in anal squamous neoplastic lesions. PMID: 24335642
KRT17 is necessary for oncogenic transformation in Ewing sarcoma and accounts for much of the GLI1-mediated transformation function but via a mechanism independent of AKT signaling. PMID: 24043308
Overexpression of keratin 17 is associated with epithelial ovarian cancer. PMID: 23430585
a novel mutation in a Chinese pedigree of pachyonychia congenita type 2 with typical clinical presentations and an autosomal dominant inheritance pattern PMID: 23278621
We identified a known mutation in the KRT17 gene in a family with steatocystoma PMID: 22639854
Keratin-17 expression is correlated with tumor progression in gastric adenocarcinoma and may serve as a biomarker for poor prognosis. PMID: 22695933
IL-22 up-regulates K17 expression in keratinocytes in a dose-dependent manner through STAT3- and ERK1/2-dependent mechanisms. PMID: 22808266
Keratin 17 is a therapeutic target for the treatment of psoriasis [review] PMID: 22795618
We observed a higher likelihood of oral leukokeratosis in individuals harboring KRT6A mutations, and a strong association of natal teeth and cysts in carriers of a KRT17 mutation. PMID: 22264670
Data indicate that cytokeratin 17 (CK17) expression could be associated with the differentiation and the malignancy of oral squamous cell carcinoma (OSCC). PMID: 22466643
A report on homozygosity for dominant missense mutations in keratin 17 that modify the pachyonychia congenita phenotype. PMID: 22336949
Both moesin and KRT17 demonstrated a tendency of increased expression as pT stage advanced. PMID: 22076435
a novel interaction involving K17 and AnxA2 and identify AnxA2 as a potential regulator of keratin filaments. PMID: 22235123
Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion PMID: 22006917
The data suggested that IL-17A can upregulate keratin-17 expression in keratinocytes in a dose-dependent manner through STAT1- and STAT3-dependent mechanisms. PMID: 21796151
AIRE expression in HaCaT epidermal keratinocytes, as well as its interaction with K17, was confirmed. PMID: 21356351
KRT17 is upregulated in gastric adenocarcinoma and is associated with tumor progression. PMID: 21443102
mutation of KRT17 may play a major role in the pathogenesis of this pedigree with pachyonychia congenita type 2. PMID: 21287500
Overexpression of KRT17 is associated with basal-like phenotype in breast cancer. PMID: 19882246
CK17 expression is significantly higher in thyroid papillary carcinoma than benign thyroid tissue; and this characteristic can have important diagnostic value. PMID: 14761598
Mutation in second half of 1A domain of K17 might delay onset of clinical phenotype. PMID: 15102078
Epitopes S1 (118-132), S2 (169-183), S4 (323-337) and S4 (348-362) are immunodominant DR B1-restricted T cell epitopes for psoriasis. S1 (118-132) contains the ALEEAN sequence. Others with different amino acid sequence have not been reported before. PMID: 15795121
KRT 17 seemed to be the most accurate marker for the diagnosis of micrometastases of a size >450 mum. PMID: 16638858
findings showed that out of all cytokeratins, CK17 was up-regulated strongest in oral squamous cell carcinoma compared to normal samples, and over-expression was most significantly associated with diagnosis PMID: 17786476
The mutation p.M88K is in the helix initiation motif (HIM) of KRT17, where 13 of the reported 14 mutations of KRT17 in PC-2 have been mapped, and the residue M88 of the HIM is also a mutation hotspot of other keratin disorders (http://www.interfil.org/). PMID: 18547302

Hide All

Involvement in disease

Pachyonychia congenita 2 (PC2); Steatocystoma multiplex (SM)

Subcellular Location

Cytoplasm.

Protein Families

Intermediate filament family

Tissue Specificity

Expressed in the outer root sheath and medulla region of hair follicle specifically from eyebrow and beard, digital pulp, nail matrix and nail bed epithelium, mucosal stratified squamous epithelia and in basal cells of oral epithelium, palmoplantar epider

Database Links

HGNC: 6427

OMIM: 148069

KEGG: hsa:3872

STRING: 9606.ENSP00000308452

UniGene: Hs.2785

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA914278A0HU
Size	US$210
	Order now
Image	Immunofluorescence staining of Hela cell with CSB-RA914278A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L). Overlay Peak curve showing Hela cells stained with CSB-RA914278A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

KRT17 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background